



Application No. (if known): 09/674,462

Attorney Docket No.: 02292/000H795-US0

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. \_\_\_\_\_ in an envelope addressed to:

**2982104097-US**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on October 28, 2003  
Date

Signature

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.


Response to Office Action (11 pages)  
One Month Request for Extension of Time Under 37 CFR 1.136(a) (1 page)  
Fee Transmittal (1 page)  
Transmittal Form (1 page)  
Check in the amount of \$55.00  
Tab 1 (2 pages)  
Substitute Sequence Listing - paper copy (16 pages)  
CRF Substitute Sequence Listing (1 diskette)  
Certificate of Express Mailing (1 page)  
Postcard



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (10-02)  
Approved for use through 10/31/2002. OMB 0651-0032

FEE TRANSMITTAL for FY 2003 <small>Patent fees are subject to annual revision.</small>		Complete if Known	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Application Number	09/674,462
TOTAL AMOUNT OF PAYMENT (\$)		Filing Date	May 8, 2001
55.00		First Named Inventor	Lechler and Dorling
		Examiner Name	Jessica Roark
		Group Art Unit	1644
		Attorney Docket No.	02292/000H795-US0
METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)	
<input checked="" type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None		3. ADDITIONAL FEES	
<input type="checkbox"/> Deposit Account		Large Entity Small Entity	
Deposit Account Number		Fee Code Fee (\$)	Fee Code Fee (\$)
Deposit Account Name		Fee Description	
The Commissioner is hereby authorized to: (check all that apply)		Fee Paid	
<input type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments			
<input type="checkbox"/> Charge any additional fee(s) during the pendency of this application			
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.			
FEE CALCULATION			
1. BASIC FILING FEE			
Large Entity Small Entity			
Fee Code Fee (\$)	Fee Code Fee (\$)	Fee Description	
1001 740	2001 370	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 510	2003 255	Plant filing fee	
1004 740	2004 370	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1) (\$)		0.00	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			
Total Claims ** =		Extra Claims Fee from below Fee Paid	
Independent Claims ** =			
Multiple Dependent			
Large Entity Small Entity			
Fee Code Fee (\$)	Fee Code Fee (\$)	Fee Description	
1202 18	2202 9	Claims in excess of 20	
1201 84	2201 42	Independent claims in excess of 3	
1203 280	2203 140	Multiple dependent claim, if not paid	
1204 84	2204 42	** Reissue independent claims over original patent	
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2) (\$)		0.00	
**or number previously paid, if greater; For Reissues, see above			
SUBMITTED BY		Complete (if applicable)	
Name (Print/Type)	Heather Morehouse Ettinger, Ph.D.	Registration No. (Attorney/Agent)	51,658
Signature	Heather Morehouse Ettinger	Telephone	(212) 836-3744
		Date	October 28, 2003



UNITED STATES PATENT AND TRADEMARK OFFICE

 UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

PFF

U.S. APPLICATION NUMBER NO. 09/674,462	FIRST NAMED APPLICANT Robert Ian Lechler	ATTY. DOCKET NO. 2292/OH795
-------------------------------------------	---------------------------------------------	--------------------------------

INTERNATIONAL APPLICATION NO. PCT/GB99/01350
-------------------------------------------------

 Darby & Darby  
 805 Third Avenue  
 New York, NY 10022-7513
DUE: September 28, 2003Docketed on 8/1 by DP for

I.A. FILING DATE 04/30/1999	PRIORITY DATE 04/30/1998
--------------------------------	-----------------------------

Docketed without file ☐Attorney PFF

CONFIRMATION NO. 8594

371 FORMALITIES LETTER



\*OC000000010580960\*

Date Mailed: 07/28/2003

1-28-04

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of Annex C of the Administrative Instructions and 37 CFR 1.822 and/or 1.832, as indicated on the attached ~~marked up~~ *document* copy of the "Raw Sequence Listing."
  - The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
  - Please see the attached reason for non-compliance of the Sequence rules, that the examiner has prepared.
  - APPLICANT MUST PROVIDE:
    - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
    - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)





EXPRESS MAIL CERTIFICATE

PLEASE CHARGE ANY DEFICIENCY OR CREDIT  
ANY EXCESS IN THE FEES DUE WITH THIS  
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-  
0100

Date \_\_\_\_\_ Label No. \_\_\_\_\_  
I hereby certify that, on the date indicated above, this paper or fee was  
deposited with the U.S. Postal Service & that it was addressed for delivery  
to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450  
by "Express Mail Post Office to Addressee" service.

\_\_\_\_\_  
Name (Print)

\_\_\_\_\_  
Signature

Customer No.: 07278

File No.: 02292/000H795-US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lechler and Dorling

Serial No.: 09/674,462

Group Art Unit: 1644

Filed: May 8, 2001

Examiner: Jessica Roark

Confirmation No.: 8594

For: IMMUNOSUPPRESSION BY BLOCKING T CELL CO-STIMULATION SIGNAL 2  
(B7/CD28 INTERACTION)

-----  
**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Application  
containing Nucleotide and/or amino Acid Sequence Disclosures mailed on July 28, 2003, please  
consider the following amendments and remarks. Amendments to the specification begin on  
page 3 of this paper. Remarks begin on page 9 of this paper. Submitted simultaneously herewith  
is (i) a Petition for ONE (1) MONTH Extension of Time up to and including October 28, 2003  
accompanied by the required fee, (ii) paper copy of the Substitute Sequence Listing and CRF of

the substitute sequence listing (1 diskette), (iii) fee transmittal sheet, and (iv) Tab 1 (NCBI printout showing sequence disclosed in Parsons et al. reference).

It is believed that no fee other than the fee for one month's extension of time is due. Should the United States Patent and Trademark Office determine that any other fee(s) is due or that any refund is owed for this application, the Commissioner is hereby authorized and requested to charge the required fee(s) and/or credit the refund(s) owed to our Deposit Account No. 04-0100.